OTCM
HCIL
Market cap26mUSD
Oct 08, Last price
0.03USD
1D
-33.93%
1Q
-72.08%
Jan 2017
231.68%
Name
Heyu Biological Technology Corp
Chart & performance
P/E
—
P/S
6.06
EPS
—
Div yield, %
—
Shrs. gr., 5y
-7.33%
Rev. gr., 5y
%
Revenues
3m
+7.14%
Net income
-472k
L+24.54%
CFO
-7m
L
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Heyu Biological Technology Corporation, alongside its subsidiaries, focuses on the research, development, and production of healthcare equipment. A key area of its present work involves developing the Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber, a medical device intended for cancer treatment. This innovative equipment is designed to induce cold nuclear fusion via cosmic ray muons within a contained environment to combat the disease. The company, incorporated in 1987 and headquartered in Xiamen, People's Republic of China, was formerly known as Pacific WebWorks, Inc., before adopting its current name, Heyu Biological Technology Corporation, in June 2018.
Key people
Siong Ang Ban
Chairman of the Board, President, Chief Executive Officer · since 2018
K. Lance Lance Bell
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer · since 2012
Wei Li Wendy
Chief Financial Officer · since 2018
Seng Tan Hung
Executive Director · since 2018
Kwee Huwa Tan
Director · since 2018
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||